Showing results (1-10 of 532) with videos related to
Sort By:
Pageof 54
Plos One|October 1, 2015
Improved Estimation of Human Lipoprotein Kinetics with Mixed Effects ModelsMartin Berglund, Martin Adiels, Marja-Riitta Taskinen, et al.Current Diabetes Reports|March 28, 2008
Fatty liver, insulin resistance, and dyslipidemiaMartin Adiels, Marja-Riitta Taskinen, Jan BorénCurrent Opinion in Lipidology|November 30, 2016
Kinetics of plasma triglycerides in abdominal obesityElias Björnson, Martin Adiels, Marja-Riitta Taskinen, et al.Clinica Chimica Acta; International Journal of Clinical Chemistry|February 11, 2014
Postprandial hypertriglyceridemia as a coronary risk factorJan Borén, Niina Matikainen, Martin Adiels, et al.Frontiers in Physiology|December 5, 2015
Kinetic Studies to Elucidate Impaired Metabolism of Triglyceride-rich Lipoproteins in HumansMartin Adiels, Adil Mardinoglu, Marja-Riitta Taskinen, et al.Arteriosclerosis, Thrombosis, and Vascular Biology|June 21, 2008
Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndromeMartin Adiels, Sven-Olof Olofsson, Marja-Riitta Taskinen, et al.Current Opinion in Lipidology|May 9, 2006
Diabetic dyslipidaemiaMartin Adiels, Sven-Olof Olofsson, Marja-Riitta Taskinen, et al.Arteriosclerosis, Thrombosis, and Vascular Biology|June 11, 2005
Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemiaMartin Adiels, Jan Borén, Muriel J Caslake, et al.Journal of Lipid Research|October 19, 2004
A new combined multicompartmental model for apolipoprotein B-100 and triglyceride metabolism in VLDL subfractionsMartin Adiels, Chris Packard, Muriel J Caslake, et al.Current Atherosclerosis Reports|September 11, 2016
Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?Marja-Riitta Taskinen, Jan BorénPageof 54